The Race to Find a Cure
STEPHANIE VEYRUN-MANETTI | CANADA COUNTRY LEAD, SANOFI
Sanofi’s goal is to become the industry leader in immunology. We focus on finding treatments for type 2 inflammatory diseases. It is the reason we put so much effort into Dupixent, jointly developed with Regeneron.
KEVIN FITZGERALD | CSO, ALNYLAM PHARMACEUTICALS
If you have a disease where something is being produced too much, imagine an overflowing sink. You can either keep mopping the floor, which is what antibodies do, or you can turn down the faucet and let the drain catch up – what RNAI therapeutics do.
WILLIAM LEWIS | CHAIR & CEO, INSMED
Rare disease innovation has been the success story of the last two or three decades since the Orphan Drug Act aligned the FDA with the companies that were trying to develop therapies in this space.